Actinium Pharmaceuticals awarded director Shetty Ajit 61,600 shares at $0 per share on 2026-09-02. After the transaction, Ajit owned 62,357 shares and held 92,400 derivative securities. The post-award holdings give investors a direct view of Ajit’s reported Equity and derivative interests.
Key Highlights
- Shetty Ajit received 92,400 derivative securities from Actinium Pharmaceuticals on 2 September 2026.
- Ajit’s post-transaction derivative securities balance was 92,400.
- The transaction carried SEC transaction code A.
Actinium Pharmaceuticals, Inc. (AMEX: ATNM) awarded director Shetty Ajit 61,600 shares at $0 per share on 2 September 2026. After the transaction, Ajit owned 62,357 shares.
92,400 Derivative Securities Recorded
Ajit also received 92,400 derivative securities from Actinium Pharmaceuticals on 2 September 2026. His post-transaction holdings included 92,400 derivative securities. The transaction was recorded under SEC code A. The award covered Actinium Pharmaceuticals shares at a price of $0 per share.
FAQs
Q: How many Actinium Pharmaceuticals shares did Shetty Ajit receive?
A: Shetty Ajit received 61,600 Actinium Pharmaceuticals shares at $0 per share on 2 September 2026. He owned 62,357 shares after the transaction.
Q: What was the impact of the ATNM director award?
A: The transaction left Shetty Ajit with 62,357 Actinium Pharmaceuticals shares. It also showed 92,400 derivative securities in his post-transaction holdings.
Q: How many derivative securities does Shetty Ajit hold?
A: Shetty Ajit held 92,400 derivative securities after the Actinium Pharmaceuticals transaction. The award was recorded on 2 September 2026 under SEC code A.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.